Wasatch Advisors LP bought a new stake in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,437,960 shares of the company’s stock, valued at approximately $5,752,000. Wasatch Advisors LP owned about 2.35% of TriSalus Life Sciences at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Wells Fargo & Company MN grew its stake in TriSalus Life Sciences by 138.3% during the 4th quarter. Wells Fargo & Company MN now owns 34,914 shares of the company’s stock worth $244,000 after buying an additional 20,261 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in TriSalus Life Sciences in the 1st quarter valued at approximately $187,000. Millennium Management LLC increased its position in TriSalus Life Sciences by 17.7% in the 3rd quarter. Millennium Management LLC now owns 35,612 shares of the company’s stock valued at $166,000 after acquiring an additional 5,359 shares during the period. Deutsche Bank AG acquired a new position in TriSalus Life Sciences during the 4th quarter worth $164,000. Finally, MetLife Investment Management LLC bought a new position in shares of TriSalus Life Sciences in the fourth quarter worth $127,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
TLSI has been the topic of a number of recent analyst reports. Lake Street Capital cut their price objective on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Weiss Ratings downgraded shares of TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Canaccord Genuity Group lowered their price objective on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, March 6th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, TriSalus Life Sciences presently has a consensus rating of “Hold” and a consensus price target of $7.50.
TriSalus Life Sciences Price Performance
Shares of NASDAQ TLSI opened at $4.73 on Friday. TriSalus Life Sciences, Inc. has a twelve month low of $2.20 and a twelve month high of $7.95. The company has a current ratio of 5.78, a quick ratio of 5.46 and a debt-to-equity ratio of 2.58. The firm has a 50-day moving average of $3.87 and a two-hundred day moving average of $4.79. The company has a market capitalization of $290.52 million, a price-to-earnings ratio of -3.35 and a beta of 0.48.
Insider Buying and Selling
In other TriSalus Life Sciences news, Director Michael P. Stansky bought 200,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average cost of $2.50 per share, with a total value of $500,000.00. Following the completion of the purchase, the director directly owned 399,698 shares in the company, valued at approximately $999,245. This trade represents a 100.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Mats Wahlstrom bought 60,000 shares of TriSalus Life Sciences stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average price of $2.53 per share, with a total value of $151,800.00. Following the completion of the acquisition, the director directly owned 147,555 shares of the company’s stock, valued at $373,314.15. This represents a 68.53% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 719,682 shares of company stock worth $1,804,176 in the last ninety days. 16.30% of the stock is currently owned by corporate insiders.
TriSalus Life Sciences Profile
TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.
The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.
Read More
- Five stocks we like better than TriSalus Life Sciences
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
